Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

86 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-31

Study Completion Date

2017-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease. In this study, our aim is to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development, Feasibility Testing and Validation of a Survey Set to Measure Patient-Reported Outcomes Among Hemodialysis Patients in Turkey

NCT05441020

Renal Failure End Stage Renal Disease

COMPLETED

Evaluation of s100β, NSE and GFAP Levels in Renal Transplantation

NCT04042272

Kidney Transplant; Complications Neurologic Manifestations Uremic Encephalopathy

COMPLETED

Risk Factors for Postoperative Fever and Sepsis Following Retrograde Intrarenal Surgery

NCT07295925

Urolithiasis

NOT_YET_RECRUITING

Triglyceride/High-density Lipoprotein Cholesterol Ratio in Chronic Kidney Disease

NCT02113462

Chronic Kidney Disease

COMPLETED

Contrast Nephropathy Associated FFA

NCT06418542

Contrast-induced Nephropathy Acute Kidney Injury

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease worldwide. Numerous studies have been conducted in order to identify the etiology of this debilitating disease. Beyond the etiological research, however, few studies managed to demonstrate the possible predictors of disease progression in patients. Therefore, we aim to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glomerulonephritis Focal Segmental Glomerulosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group

Patients with biopsy-proven primary focal segmental glomerulosclerosis.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with biopsy-proven primary focal segmental glomerulosclerosis.
* Patients who have a renal biopsy available for reviewing including 8 or more glomeruli.
* Patients who have been followed-up for at least 6 months or have progressed to primary outcome regardless the duration of follow-up.

Exclusion Criteria

* Patients who have secondary focal segmental glomerulosclerosis attributable to any other condition (e.g., obesity, HIV, relevant drug exposure).
* Patients who have a genetic mutation or variation creating a tendency for developing focal segmental glomerulosclerosis.
* Patients who are unwilling or unable to consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No